Status:
UNKNOWN
Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer
Lead Sponsor:
Bulent Ecevit University
Conditions:
Breast Cancer
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Sentinel lymph node (SLN) biopsy is the gold standard method to stage axilla in breast cancer. The aim of the study is to compare the efficiency of various methods to identify SLN is breast cancer pat...
Detailed Description
Various markers has been used for SLN biopsy including isosulfan blue (patent blue), indocyanine green (ICG), radioisotope colloid (RAIC) and ultrasound (US) with several advantages and disadvantages....
Eligibility Criteria
Inclusion
- Histologically confirmed primary breast cancer by core needle, incisional or excisional biopsy
- cN0 patients
- In patients with abnormal axillary lymph nodes sonographically US-guided FNA cytology of these nodes were performed and FNA cytology negative patients planed to undergo SLNB with different mapping techniques.
Exclusion
- Patients with neoadjuvant therapy
- Patients with pathological diagnosed ductal carcinoma in situ by excisional biopsy
- Patients with pathologically proven axillary disease
- Patients with T4d tumor
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04274946
Start Date
January 1 2019
End Date
January 1 2025
Last Update
February 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bülent Ecevit University
Zonguldak, Turkey (Türkiye), 67600